logo

Atossa Therapeutics Inc. (ATOS)



Trade ATOS now with
  Date
  Headline
7/15/2021 9:03:35 AM Physician-Scientist Steven Quay And Investigators Provide Science-Based Analysis Of Origin Of COVID-19 To US Congress
3/11/2021 10:29:26 AM Atossa Therapeutics Gets FDA Safe To Proceed Letter For Treatment Of An Ovarian Cancer Patient With Oral Endoxifen
11/10/2020 10:06:13 AM Atossa : Preliminary Phase 1 Study Shows Safety And Tolerability Of AT-301 Nasal Spray Being Developed For COVID-19
10/19/2020 10:16:06 AM Atossa Completes Enrollment Of Phase 1 Study Of AT-301 Nasal Spray Being Developed For Coronavirus Causing COVID
9/17/2020 9:38:42 AM Atossa Receives Second Positive Interim Safety Assessment In Study Of AT-301 Nasal Spray
8/3/2020 9:43:21 AM Atossa Gets Australian Govt Approval To Open Clinical Study Of AT-301 Nasal Spray Being Developed To Treat COVID-19
7/30/2020 9:34:07 AM Atossa Reports Interim Findings Following 18 Months Of Expanded Access Study Of Endoxifen
7/15/2020 10:08:30 AM Atossa Announces Successful Results From In Vitro Testing Of AT-301, Proprietary COVID-19 Nasal Spray Drug Candidate
6/11/2020 9:33:30 AM Atossa Therapeutics Reports Availability Of Manuscript On Results From In Vitro Testing Of COVID-19 Drug, AT-H201
5/7/2020 9:37:30 AM Atossa Report Positive Interim Results From Phase 2 Study Of Oral Endoxifen